Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
62 (26%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-MIDODRINE | 5MG | TABLET | Resolved | 2022-01-21 | 2022-04-29 | 153278 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2021-12-17 | 2022-01-06 | 151347 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2023-12-22 | 2024-02-09 | 214244 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2024-04-12 | 2024-05-24 | 225002 |
| APO-MIRTAZAPINE | 45MG | TABLET | Resolved | 2024-04-26 | 2024-05-24 | 226333 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2024-05-31 | 2024-06-28 | 229392 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2024-08-22 | 2024-09-06 | 235711 |
| APO-MIRTAZAPINE | 45MG | TABLET | Resolved | 2024-09-12 | 2024-09-20 | 237369 |
| APO-MIRTAZAPINE | 45MG | TABLET | Resolved | 2017-10-03 | 2017-10-17 | 24271 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2018-01-10 | 2018-03-25 | 35545 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2018-01-17 | 2018-03-25 | 36316 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2020-01-08 | 2020-02-10 | 102572 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2020-04-13 | 2020-04-27 | 111921 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2020-11-19 | 2020-12-28 | 128612 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2021-03-19 | 2021-03-30 | 136026 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2017-03-10 | 2017-05-10 | 393 |
| APO-MIRTAZAPINE | 45MG | TABLET | Resolved | 2017-03-10 | 2017-03-23 | 396 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2017-03-22 | 2017-05-02 | 3909 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2017-05-04 | 2017-06-15 | 8874 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2017-05-16 | 2017-06-15 | 10429 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |